Jae Park, MD, shares an overview of available therapeutic options for patients with R/R B-ALL.
Back
Updates in the Treatment of Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Jae Park, MD, reviews the current treatment landscape and emerging options for treating adults with relapsed/refractory B-cell acute lymphoblastic leukemia
Updates in the Treatment of Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Episodes
All
All
An oncologist specializing in the treatment of patients with B-ALL discusses the study design, efficacy, safety, and two-year updated results of the phase I/II ZUMA-3 study evaluating brexucabtagene autoleucel in adult patients with R/R B-ALL.
Dr. Jae Park comments on the findings from the ELIANA study and tisagenlecleucel as a potential option for adults with R/R B-ALL.
Practical considerations for treatment selection in patients who progress on CAR T-Cell therapy.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5